Eli Lilly announced that its oral GLP-1 medication, orforglipron, may provide weight loss results comparable to those of weekly GLP-1 injections. The company revealed on Thursday that participants in two Phase 3 trials lost an average of 27.3 pounds while taking the pill. These trials involved over 3,000 adults who were overweight or obese.

Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, emphasized the significance of this development. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," he stated.

Eli Lilly plans to submit orforglipron for regulatory review by the end of the year. The company is also preparing for a global launch to meet the urgent public health need for effective obesity treatments. This announcement marks a significant step in the ongoing efforts to address obesity, a condition affecting millions of people worldwide.

As the situation evolves, further updates will be provided.